A study of the ReCor Medical Paradise System in Clinical Hypertension

A study of the ReCor Medical Paradise System in Clinical Hypertension
Recruiting
18 years - 99 years
All
Phase N/A
10 participants needed
1 Location

Brief description of study

The objective of TRIO CAP is to continue to collect safety and effectiveness data on the Paradise System in hypertensive subjects inadequately controlled with three antihypertensive medications, similar to those randomized in the RADIANCE-HTN Study TRIO Cohort, until the Paradise Ultrasound Renal Denervation System becomes commercially available. Reduction in average daytime ambulatory systolic BP from baseline to 2 months post procedure MR angiography

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hypertension
  • Age: 18 years - 99 years
  • Gender: All

Male or Female, Age 18 or Older, Completion of RADIANCE-HTN Study

Updated on 04 Aug 2024. Study ID: 850354

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center